Curated News
By: NewsRamp Editorial Staff
May 20, 2025

BioCorRx Inc. Acquires LUCEMYRA, an FDA-Approved Opioid Withdrawal Medication

Reddit Discuss on LinkedIn Discuss on Substack participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • BioCorRx Inc. acquired LUCEMYRA® (lofexidine), the FDA-Approved Opioid Withdrawal Medication, giving them a competitive edge in the substance abuse treatment market.
  • LUCEMYRA® is a non-opioid medication approved by the FDA to alleviate opioid withdrawal symptoms by reducing the release of norepinephrine.
  • BioCorRx's acquisition of LUCEMYRA® provides critical relief for patients undergoing opioid detoxification, improving the quality of life for individuals struggling with substance abuse.
  • Research funded by NIH to develop BICX104, a naltrexone implant for methamphetamine use disorder, offers hope for combating the growing public health challenge of MUD.

Impact - Why it Matters

This news highlights the acquisition of LUCEMYRA by BioCorRx Inc., marking a significant development in the treatment of opioid withdrawal. The availability of non-opioid medication like LUCEMYRA offers a crucial solution for patients undergoing opioid detoxification. Additionally, the ongoing research for sustained-release naltrexone products demonstrates BioCorRx's commitment to addressing substance use disorders and improving treatment options.

Summary

BioCorRx Pharmaceuticals Inc. Acquired LUCEMYRA® (lofexidine), an FDA-Approved Opioid Withdrawal Medication, from USWM, LLC

BioCorRx Inc. announced the acquisition of LUCEMYRA, an FDA-approved medication for opioid withdrawal, from USWM, LLC. LUCEMYRA is the first non-opioid medication approved by the FDA to alleviate opioid withdrawal symptoms. The move is expected to drive revenue growth for BioCorRx Inc. with notable net product revenues from LUCEMYRA.

BioCorRx Pharmaceuticals Inc. is also developing sustained-release naltrexone products, with research supported by a significant grant from the National Institutes of Health. The company aims to address methamphetamine use disorder, a significant public health challenge, with the development of BICX104 as a potential treatment option.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, BioCorRx Inc. Acquires LUCEMYRA, an FDA-Approved Opioid Withdrawal Medication

blockchain registration record for this content.